Abstract
Myocardial infarction [MI] is the major cause of death in western countries. The loss of cardiomyocytes and insufficient blood supply are the most frequent causes for the development of chronic heart failure [CHF]. Current therapy in patients after MI is focused on shortening the time of ischemia by restoration of coronary blood flow and the prevention of ventricular remodeling and development of heart failure. Despite development of new pharmacological agents mortality rate in the patients with CHF is still very high.
Zie: Summary
Original language | English |
---|---|
Qualification | Doctor of Philosophy |
Supervisors/Advisors |
|
Publisher | |
Print ISBNs | 9789036732765 |
Publication status | Published - 2008 |
Keywords
- Hartzwakte, Stamceltherapie, Angiotensinen Proefschriften (v
- cardiologie